PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.06 - 0.06
0.06 - 0.24
2.78M / 3.59M (Avg.)
-1.55 | -0.04
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2848309.72%
10Y CAGR of 2848309.72% while CRN.AX is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
664.00%
5Y CAGR of 664.00% while CRN.AX is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
54.86%
Positive 3Y CAGR while CRN.AX is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
509.72%
OCF/share CAGR of 509.72% while CRN.AX is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
92445.56%
OCF/share CAGR of 92445.56% while CRN.AX is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
379.37%
Positive 3Y OCF/share CAGR while CRN.AX is negative. John Neff might see a big short-term edge in operational efficiency.
252.17%
10Y net income/share CAGR of 252.17% while CRN.AX is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
14.85%
Net income/share CAGR of 14.85% while CRN.AX is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
709.76%
3Y net income/share CAGR above 1.5x CRN.AX's 59.22%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-93.13%
Negative equity/share CAGR over 10 years while CRN.AX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
130.19%
Equity/share CAGR of 130.19% while CRN.AX is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
36.04%
Positive short-term equity growth while CRN.AX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.